MARKET

CRBP

CRBP

Corbus Pharmaceu
NASDAQ
11.03
-0.95
-7.93%
After Hours: 11.03 0 0.00% 19:21 05/15 EDT
OPEN
11.93
PREV CLOSE
11.98
HIGH
11.93
LOW
11.00
VOLUME
167.95K
TURNOVER
--
52 WEEK HIGH
20.56
52 WEEK LOW
6.53
MARKET CAP
204.36M
P/E (TTM)
-1.8979
1D
5D
1M
3M
1Y
5Y
1D
Corbus Pharmaceuticals Holdings Inc. Stock Slides 7.9%, Underperforms Peers
Dow Jones · 8h ago
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
TipRanks · 1d ago
*Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors
Dow Jones · 1d ago
CORBUS PHARMACEUTICALS APPOINTS PHARMA INDUSTRY VETERAN BRENT PFEIFFENBERGER TO BOARD OF DIRECTORS
Reuters · 1d ago
RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)
TipRanks · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Advances 6.3%, Outperforms Peers
Dow Jones · 2d ago
Corbus Pharmaceuticals Is Maintained at Buy by Jefferies
Dow Jones · 2d ago
Corbus Pharmaceuticals Price Target Cut to $33.00/Share From $36.00 by Jefferies
Dow Jones · 2d ago
More
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Webull offers Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ: CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.